Insight Molecular Diagnostics Inc. IMDX
1.75 USD -0.11 (-5.91%)
As ofNov 17, 2026, 12:37 PM EST
1.63 Day range 1.79
1.63 52-week range 7.51
- YTD
- -76.67%
- 1 year
- -73.88%
News
globenewswire.com Insight Molecular Diagnostics Announces Pricing of $15 Million Public Offering NASHVILLE, Tenn., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx,” “we,” “us,” “our,” or the “Company”) today announced the pricing of its underwritten…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Aytu BioPharma (NASDAQ:AYTU) shares rose 45.0% to $2.64 during Tuesday's pre-market session. The market value of their outstanding shares is at $19.7 million. The company's, Q1 earnings came…
seekingalpha.com Insight Molecular Diagnostics Inc. (IMDX) Q3 2026 Earnings Call Transcript Insight Molecular Diagnostics Inc. (IMDX) Q3 2026 Earnings Call Transcript
marketbeat.com What Oncocyte (IMDX) Said on Its Q3 Earnings Call Insight Molecular Diagnostics (IMDX) expects to respond before a January 2027 deadline to the U.S. Food and Drug Administration's request for more information about its GraftAssureDx kidney…
globenewswire.com IMDx Reports Third Quarter 2026 Results and Provides Corporate Update NASHVILLE, Tenn., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its third…
globenewswire.com Insight Molecular Diagnostics Announces Proposed Public Offering NASHVILLE, Tenn., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx,” “we,” “us,” “our,” or the “Company”) today announced that it has commenced an…
